Clinical Trial Update: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daratumumab, azacitidine, and dexamethasone for recurrent or refractory multiple myeloma previously treated with daratumumab was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2024-04-30